Cardiology

After highlighting the first half of the year in our top decisions from the first half of 2022, Practical Cardiology’s editorial staff fixed its gaze on the cardiology pipeline for the remainder of 2022. In this list, we highlight potential FDA Decisions and trials to watch for in the second half of the year.

Timing, urgency, and risk category of surgery were not associated with increased risk of the primary end point.

Preventable factors including obesity, hypertension, and physical activity are disparately impacting the rate of dementia among people of color.

New findings suggest low-dose rivaroxaban plus aspirin was associated with lower VTE risk compared with aspirin alone.

Reducing sedentary time and increasing physical activity may reduce the global burden of premature deaths and CVD.

A recent analysis of the ISCHEMIA program suggests invasive management of chronic coronary disease appeared to provide a greater degree of benefit in those with less advanced stages of chronic kidney disease.

An analysis of nationally representative data from NHANES cycles from 1999-2000 through 2017-2018 suggests just 6.8% of US adults had optimal cardiometabolic health.

Our latest case report from Brady Pregerson, MD, features a woman in her mid-40s presenting with palpitations the past 2 hours. Check out the EKG and determine the correct diagnosis!

Dr. Gregory Weiss provides perspective on a recent study suggesting women with gestational hypertension were at an increased risk of chronic hypertension later in life.

Event rates were inversely proportional to kidney function in patients with chronic coronary disease.

The first half of 2022 has seen its fair share of FDA decisions, both approvals and CRLs. In this article, we recap the top regulatory events in cardiorenal metabolic health from the first half of the year, including news related to empagliflozin, mavacamten, and more.

A substantial number of individuals (nearly 40%) reached arterial stenosis of at least 50%, according to the findings.

Varenicline was efficacious at weeks 12, 24, and 52 of the trial compared with placebo in a smoking cessation program.

New research from the first study to use the AHA's Life's Essential 8 to assess cardiovascular health at a population level details the lack of optimized cardiovascular health among adults and children in the US.

On June 29, the American Heart Association announced Life's Simple 7 is a thing of the past and will now include a section dedicated to the impact of sleep on cardiovascular health with the debut of Life's Essential 8.

At HiD 2022, Dr. Budoff discusses the use and utility of coronary calcium scoring for risk stratification

Dr. Martin explores the explosion of new consumer technologies and how to close the gap in disparities between data collection and using the data in practice.

Dr. Gregory Weiss provides perspective on a recent study detailing the risks of thrombosis observed with different COVID-19 vaccines among patients from a group of countries in Europe.

Dr. Ray discusses the impact of current practice on cholesterol goal attainment and what more needs to be done.

Our cardiology month in review spotlights the most popular content from the past month. The top content from June 2022 includes new USPSTF recommendations, DECAAF II, the latest edition of Don’t Miss a Beat, & more!

Dr. Green discusses the potential of combination therapy to reduce cardiovascular and kidney outcomes in people with type 2 diabetes.

Dr. Joseph discusses modalities to address cardiometabolic disease in individuals around the country, from lifestyle management to policy-level changes.

New research from Indiana University details the impact of an invasive management strategy compared to medical management among patients with NSTEMI and chronic kidney disease across the spectrum of CKD severity.

Dr. Gregory Weiss provides perspective on recent data detailing the acceleration of heart failure progression associated with a diagnosis of diabetes mellitus.

An analysis of insurance claims data from 2016-2018 suggests cardiac rehabilitation attendance was 31% lower among Asian individuals, 19% lower among Black individuals, and 43% lower among Hispanic individuals compared to their White counterparts in models adjusted for income, age, sex, hypertension, diabetes, depression, ischemic stroke, and education level.

Data from a Johns Hopkins Medicine-led analysis provide insight into the risk of cardiovascular complications among women with polycystic ovary syndrome during delivery hospitalizations compared to their counterparts without PCOS.

On June 21, the USPSTF released a new recommendation statement related to use of vitamin, mineral, or multivitamin supplements for the prevention of cancer and cardiovascular disease in adult patients, which replace the organization's 2014 recommendations on the subject.

A retrospective analysis comparing statin users and nonusers details the significant declines in arterial stiffness progression among patients of high atherosclerotic risk based on statin use and adherence in a cohort of more than 5000 patients.

Using National Inpatient Sample data from a nearly 2 decade period, investigators detail the increased risk of cardiovascular complications among women with PCOS during delivery hospitalizations and predictors of this increased risk.